Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Carbon Monoxide Reverses Diabetic Gastric Problem In Mice
Mayo Clinic researchers have shown that very low doses of inhaled carbon monoxide in diabetic mice reverses the condition known as gastroparesis or delayed stomach emptying, a common and painful complication for many diabetic patients. The findings were presented on June 1 at Digestive Disease Week in Chicago.

Ethicists Debate New York State's Decision To Pay Egg Donors Who Aid Stem Cell Research
New York state"s decision last month to allow state-funded embryonic stem cell researchers to pay women for donating their eggs had drawn support from many scientists and doctors but fueled debate among some ethicists, Long Island Newsday reports. The state"s Empire State Stem Cell Board said that researchers can pay women up to $10,000 as compensation for their time and the invasive nature of the procedure.Scientists and research advocates say the decision could boost important research into cures of serious diseases while attracting investments and new jobs to the state. Opponents raise ethical concerns about using taxpayer money for research that some people find morally objectionable. Some also contend that payment might exploit low-income women, according to Newsday. The National Academy of Sciences and NIH do not permit payments to research participants beyond reimbursement.Thomas Berg -- director of the Westchester Institute for Ethics and the Human Person and a Roman Catholic priest opposed to embryonic stem cell research -- cast the sole dissenting vote in the stem cell board"s decision. Berg said the board ignored his suggestions to open the discussion to the public. However, Samuel Packer -- a member of the board and chair emeritus at the North Shore-Long Island Jewish Health System"s Department of Ophthalmology -- said the decision was made during a public meeting following a "long, lively debate." Packer said, "At some point the dissenting voice can"t stop the progress of science or anything else in society." He added, "There is a direct link between having better eggs and doing better research" (Ochs, Long Island Newsday, 7/9).
News of the day
King Provides Additional Information On The REMOXY(R) NDA Resubmission Plan
King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY(R) New Drug Application (NDA). The Company is not required by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate-to-severe chronic pain. However, as part of the resubmission plan, and in order to strengthen the NDA, King plans to conduct a likeability study and a pharmacokinetic trial in volunteers. The Company continues to anticipate the resubmission could occur mid-year 2010.
Medical Devices

Important Modulator Of Immune Cell Entry Into The Brain Discovered

Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells. A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The researchers showed that this bradykinin receptor 1 (B1) controls the infiltration of immune cells into the CNS. When they activated B1 in mice with encephalitis, they were able to slow down the crossing of the immune cells through the blood-brain-barrier into the CNS. As a result, the inflammation markedly decreased. Commenting on the findings, Helen Yates, Multiple Sclerosis Re Centre Chief Executive said, "This is a very important piece of research. We have long known that the crossing of immune cells into the CNS is a major problem in MS. This work shows that inflammation can be decreased and hopefully will lead to further research into prevention of the inflammatory response completely." The work by Dr. Ulf Schulze-Topphoff, Prof. Orhan Aktas, and Professor Frauke Zipp (Cecilie Vogt-Clinic, Charité - Universitätsmedizin Berlin, Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch and NeuroCure Research Center) together with researchers in Canada and the USA may unveil a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis (MS) (Nature Medicine, doi 10.1038/nm.1980)*. It has been known for a long time that T cells can attack the body"s own structures and, if they infiltrate the CNS, cause diseases such as multiple sclerosis (MS). The T cells damage the myelin sheath, the material that surrounds and protects the fibers of nerve cells. This damage slows down or blocks messages between the brain and the body, leading to various symptoms of MS such as impaired movements. The molecular analysis of damaged tissue from patients with MS led the researchers to the B1-receptor. The data they evaluated showed that two different pathways known to play a crucial role in the cardiovascular area also seem to play an important role in the CNS: namely, the renin-angiotensin-system, and the kallikrein-kinin-system, the latter of which the researchers in Berlin put their focus on. The B1-receptor is part of the kallikrein-kinin-system. Together with Professor Alexandre Prat from the Université de Montréal, Montréal, Canada, and Professor Lawrence Steinman from Stanford University in Stanford, California, USA, the researchers in Berlin detected the B1-receptor on T cells of MS patients as well as on T cells of mice with encephalitis, an inflammation of the brain. The disease got worse in those mice that lacked B1 on their T cells. Therefore, using a certain substance (Sar-[D-Phe]desArg9-bradykinin), they activated the receptor in mice which had B1 on their T cells. As a result, the entry of T cells into the CNS slowed down and the clinical symptoms of the inflammation markedly decreased. "We have discovered a control mechanism, which reduces inflammation caused by the immune system" neurologist and MDC research group leader Professor Zipp explains. "It remains to be seen if we succeed in developing a new therapy for chronic inflammation in the CNS, such as MS, in the future." Multiple Sclerosis Re Centre


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009